Provention Bio said today that it licensed an enterovirus vaccine platform that it plans to evaluate as a way to prevent the onset of Type I diabetes by vaccinating against infection by a coxsackievirus B pathogen. Previous work has shown that CVB infection could be responsible for 50% of Type I diabetes cases worldwide, according to […]
Voluntis said today its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate Sanofi‘s (NYSE:SNY) Toujeo insulin glargine. The company’s software already works with Lantus and Levemir. The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. The app gives real-time […]
Researchers from the Rovira i Virgili University have developed and patented a mobile diagnostic device that can detect tumor cells in blood, according to a study published in Scientific Reports. The team reported that the device can quantify tumor cells in a blood sample in real-time, positioning it as a tool to boost the diagnosis and treatment of […]
AntriaBio (OTC:ANTB) said today that it closed a $13 million private placement, supported by Aju Pharm, Ildong Pharmaceutical Co. and Medici Investment Co. According to the deal, investors paid $1.00 per share of common stock. Get the full story at our sister site, Drug Delivery Business News.
From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief […]
Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin delivery system since its beginnings in 2014. Just yesterday Bigfoot announced that it is partnering with Abbott, bringing together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin […]
The Feinstein Institute said this week it won a $1 million gift from the Knapp Family Foundation to launch a 4-year research program to explore bioelectronic medicine to treat diabetes. With the grant, the institute will aim to develop an implantable device that will function as an electronic pancreas to regulate diabetes patients’ glucose metabolism […]
Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems. The collaboration will bring together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform, the companies reported. Get the full story at our sister site, Drug Delivery Business News.
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema. The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent. Get the full story at our […]
Novo Nordisk (NYSE:NVO) and Glooko said today they jointly launched the Cornerstones4Care mobile application designed to aid individuals in managing their diabetes. The C4C application integrates Novo Nordisk’s diabetes knowledge and personalized patient support with Glooko’s digital platform and data analytics, the companies said, and is the 1st jointly developed product from the pair, which announced […]
Oramed Pharmaceuticals (NSDQ:ORMP) said today that the FDA scheduled an end-of-phase II meeting with the Jerusalem-based company for August 31. Oramed is developing an oral insulin capsule for the treatment of Type II diabetes. The company’s Phase IIb trial met primary and secondary endpoints, since the insulin capsule lowered patients’ blood sugar relative to a placebo. […]